{"generic":"Anthrax Vaccine Adsorbed","drugs":["Anthrax Vaccine Adsorbed","Biothrax"],"mono":{"0":{"id":"jtyzs0","title":"Generic Names","mono":"Anthrax Vaccine Adsorbed"},"1":{"id":"jtyzs1","title":"Dosing and Indications","sub":{"0":{"id":"jtyzs1b4","title":"Adult Dosing","mono":"<ul><li>safety and efficacy not established in subjects greater than 65 years of age<\/li><li><b>Anthrax, Preexposure; Prophylaxis:<\/b> (18 to 65 years of age) 0.5 mL IM x 3 doses at 0, 1 and 6 months; followed by 2 booster doses of 0.5 mL IM at 12 and 18 months; additional booster doses at 1 year intervals for those at continued risk<\/li><li><b>Anthrax, Preexposure; Prophylaxis:<\/b> (18 to 65 years of age) 0.5 mL SUBQ x 4 doses at 0, 2 and 4 weeks, and 6 months; followed by 2 booster doses of 0.5 mL SUBQ at 12 and 18 months; additional booster doses at 1 year intervals for those at continued risk<\/li><li><b>Inhalational anthrax, Postexposure; Prophylaxis:<\/b> 0.5 mL SUBQ immediately postexposure with repeat doses at 2 and 4 weeks, in conjunction with chemoprophylaxis (ciprofloxacin 500 mg or doxycycline 100 mg ORALLY twice daily); continue antibiotic therapy for 60 days<\/li><\/ul>"},"1":{"id":"jtyzs1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in pediatric patients<\/li><li><b>Inhalational anthrax, Postexposure; Prophylaxis:<\/b> anthrax vaccines have not been studied in children, but vaccine is likely to be safe and effective in pediatric patients; however, specific dosing recommendations are unavailable; regardless of the decision as to the use of the vaccine in children, postexposure antibiotic chemoprophylaxis should be administered for at least 60 days: ciprofloxacin 15 mg\/kg orally every 12 hours (max, 500 mg\/dose or 1 g\/day) or doxycycline 100 mg orally every 12 hours (greater than 8 years of age AND greater than 45 kg) or doxycycline 2.2 mg\/kg (max, 100 mg\/dose) orally every 12 hours (8 years of age and younger, OR 45 kg and under) is indicated for confirmed exposure<\/li><\/ul>"},"3":{"id":"jtyzs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Anthrax, Preexposure; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Inhalational anthrax, Postexposure; Prophylaxis<br\/>"}}},"3":{"id":"jtyzs3","title":"Contraindications\/Warnings","sub":[{"id":"jtyzs3b9","title":"Contraindications","mono":"history of anaphylactic or anaphylactic-like reaction to previous dose or any component of anthrax vaccine <br\/>"},{"id":"jtyzs3b10","title":"Precautions","mono":"<ul><li>allergic reactions, acute, including anaphylaxis have been reported<\/li><li>anthrax disease, history; may increase the potential for severe local adverse reactions<\/li><li>illness, moderate or severe; postpone preexposure vaccination schedules until after recovery<\/li><li>immunocompromised patients or those receiving concomitant immunosuppressive therapy; immune response to vaccine may by impaired<\/li><li>latex sensitivity; vial stopper contains dry natural rubber and may cause allergic reactions<\/li><li>pregnancy; vaccine can cause fetal harm<\/li><li>report suspected adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http:\/\/www.vaers.hhs.gov<\/li><\/ul>"},{"id":"jtyzs3b11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"jtyzs3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"5":{"id":"jtyzs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (IM, 15% to 48%; subQ, 53% to 71%), Injection site edema (IM, 5% to 30%; subQ, 17% to 46%), Injection site pain (IM, 13% to 20%; subQ, 12% to 22%), Injection site reaction (IM, 60% to 77%; subQ, 80% to 92%), Tenderness, Injection-site (IM, 41% to 51%; subQ, 48% to 72%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (IM, 72%; subQ, 76.1%), Reduced mobility, Arm (IM, 9% to 15%; subQ, 5% to 12%)<\/li><li><b>Neurologic:<\/b>Headache (IM, 70.4%; subQ, 78.4%)<\/li><li><b>Other:<\/b>Fatigue (IM, 70.1%; subQ, 76.8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Stevens-Johnson syndrome<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},"6":{"id":"jtyzs6","title":"Drug Name Info","sub":{"0":{"id":"jtyzs6b17","title":"US Trade Names","mono":"Biothrax<br\/>"},"2":{"id":"jtyzs6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"jtyzs6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jtyzs7","title":"Mechanism Of Action","mono":"Anthrax vaccine protects against the cytotoxic lethal and edema toxins of Bacillus anthracis by raising antibodies that deactivate the bacterium's protective antigen (PA) virulent component. The effects of the other proteins present in the vaccine are still undetermined.<br\/>"},"9":{"id":"jtyzs9","title":"Administration","mono":"<ul><li><b>Intramuscular<\/b><br\/><ul><li>shake thoroughly before use<\/li><li>use a separate sterile needle and syringe to withdraw a single dose for each patient<\/li><li>do not mix with any other substances in the syringe<\/li><li>use different injection sites for each sequential injection<\/li><li>subcutaneous route is permissible in patients at risk for hematoma formation following IM injection<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>shake thoroughly before use<\/li><li>use a separate sterile needle and syringe to withdraw a single dose for each patient<\/li><li>do not mix with any other substances in the syringe<\/li><li>use different injection sites for each sequential injection<\/li><li>subcutaneous route is permissible in patients at risk for hematoma formation following IM injection<\/li><\/ul><\/li><\/ul>"},"13":{"id":"jtyzs13","title":"Clinical Teaching","mono":"<ul><li>May cause erythema, tenderness, warmth, pruritus, or induration at injection site.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as this vaccine should be given in a fixed series of injections.<\/li><\/ul>"}}}